Nxera Pharma Co., Ltd.
4565.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | ¥94,033 | ¥117,257 | ¥174,856 | ¥154,580 |
| - Cash | ¥32,268 | ¥49,065 | ¥66,557 | ¥60,087 |
| + Debt | ¥67,900 | ¥73,973 | ¥29,734 | ¥29,271 |
| Enterprise Value | ¥129,665 | ¥142,165 | ¥138,033 | ¥123,764 |
| Revenue | ¥28,835 | ¥12,766 | ¥15,569 | ¥17,712 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Gross Profit | ¥21,219 | ¥9,664 | ¥14,643 | ¥16,779 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| EBITDA | ¥105 | -¥5,707 | ¥3,567 | ¥2,189 |
| % Margin | 0.4% | -44.7% | 22.9% | 12.4% |
| Net Income | -¥4,838 | -¥7,193 | ¥382 | ¥1,017 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS Diluted | -53.92 | -87.17 | 4.63 | 12.4 |
| % Growth | 38.1% | -1,982.7% | -62.7% | – |
| Operating Cash Flow | -¥7,718 | -¥5,273 | ¥9,952 | ¥7,095 |
| Capital Expenditures | -¥526 | -¥851 | -¥303 | -¥201 |
| Free Cash Flow | -¥8,244 | -¥6,124 | ¥9,649 | ¥6,894 |